首页 中华结核和呼吸杂志 2022年45卷07期 结核病免疫治疗专家共识（2022年版）
中华结核和呼吸杂志
期刊首页
过刊列表
高级检索
稿件发表
• 诊疗方案 •
ENGLISH ABSTRACT
结核病免疫治疗专家共识（2022年版）
中华医学会结核病学分会 
作者及单位信息
·
DOI： 10.3760/cma.j.cn112147-20220215-00120
Expert consensus on immunotherapy for tuberculosis (2022 edition)
Chinese Society of Tuberculosis, Chinese Medical Association
Yang Song
Tang Shenjie
Authors Info & Affiliations
Chinese Society of Tuberculosis, Chinese Medical Association
Yang Song
Chongqing Public Health Medical Center, Chongqing 400036
Tang Shenjie
Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149
·
DOI： 10.3760/cma.j.cn112147-20220215-00120
7090
1579
0
8
98
13
扫描转手机阅读
下载中华医学期刊APP阅读更流畅 体验更丰富
PDF下载
APP内阅读
摘要
结核病患者普遍存在免疫功能异常，机体的免疫状态和结核病的发生、发展和转归密切相关。目前临床医生对结核病的免疫治疗认识明显不足。为推动我国结核病免疫治疗新方法的应用，最大程度使结核病患者获益，中华医学会结核病学分会制定《结核病免疫治疗专家共识（2022年版）》。本共识对结核病的免疫学发病机制、免疫治疗适宜人群和免疫治疗目的分别进行了阐述，并对常用免疫治疗制剂的应用提出了推荐意见（引用证据），对其使用方法、不良反应和注意事项分别说明，以期为临床医生进行结核病免疫治疗提供参考。
音频摘要
结核病患者普遍存在免疫功能异常，机体的免疫状态和结核病的发生、发展和转归密切相关。本共识对结核病的免疫学发病机制、免疫治疗适宜人群和免疫治疗目的分别进行了阐述，并对常用免疫治疗制剂的应用提出了推荐意见（引用证据），对其使用方法、不良反应和注意事项分别说明，以期为临床医生进行结核病免疫治疗提供参考。
ABSTRACT
Patients with tuberculosis(TB) usually have abnormal immune function, and the host immunological status is closely related to the occurrence, development and outcome of TB. At present, the knowledge of immunotherapy of TB is obviously insufficient. In order to promote the application of new methods of TB immunotherapy in China and achieve the maximum possible gain of TB patients, the Chinese Society of Tuberculosis/Chinese Medical Association issued the Expert Consensus on TB Immunotherapy (2022 edition). This consensus described the immunological pathogenesis of TB, appropriate patients and goals of immunotherapy. Recommendations (reference evidence) on the application of immunotherapeutic preparations were put forward, with a description of the method of application, adverse reactions and precautions, so as to provide reference for clinical doctors for TB immunotherapy.
Yang Song,Chongqing Public Health Medical Center, Chongqing 400036, Email:
mocdef.nabuyila5gnosgnay
Tang Shenjie,Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, Email:
mocdef.aabnis.piv6011jsgnat
Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文
中华医学会结核病学分会. 结核病免疫治疗专家共识（2022年版）[J]. 中华结核和呼吸杂志,2022,45(07)：651-666.
DOI:10.3760/cma.j.cn112147-20220215-00120PERMISSIONS
Request permissions for this article from CCC.
评价本文
*以上评分为匿名评价
本文评分
0分
[累计0个]
向我们报错
版权归中华医学会所有。
未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。
除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。
结核病（tuberculosis，TB）患者普遍存在免疫功能异常，目前临床医生对活动性结核病（active tuberculosis，ATB）的免疫治疗认识明显不足。为推动我国结核病免疫治疗新方法的应用，最大程度使结核病患者获益，中华医学会结核病学分会组织专家撰写了《结核病免疫治疗专家共识（2022年版）》（简称本共识），供国内同行参考。本共识采用世界卫生组织（WHO）推荐的推荐意见分级的评估、制订及评价（GRADE）方法，对推荐意见的级别和循证医学证据的质量进行评估。强烈推荐（1级）明确显示干预措施利大于弊，有条件性推荐（2级）提示利弊不确定或无论证据级别的高低均显示利弊相当。“推荐”表示强烈推荐，“建议”表示有条件性推荐。证据质量及其定义如下。高质量（A）：对估计的效应值非常确信，估计值接近真实值，进一步研究基本不改变该估计效应值的可信度。中等质量（B）：对估计的效应值确信程度中等，估计值有可能接近真实值，但仍存在二者不相同的可能性，进一步研究有可能改变该估计效应值的可信度。低质量（C）：对估计的效应值确信程度有限，估计值与真实值可能不同，进一步研究极有可能改变该估计效应值的可信度。极低质量（D）：对估计的效应值不能确信，估计值与真实值很可能完全不同，进一步研究有可能不确定该估计效应值的可信度。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
已是订阅账户?
登录
参考文献
[1]
Martini M , Riccardi N , Giacomelli A ,et al. Tuberculosis: an ancient disease that remains a medical, social, economical and ethical issue[J]. J Prev Med Hyg, 2020,61(1Suppl 1):E16-E18. DOI:
10.15167/2421-4248/jpmh2020.61.1s1.1475
.
[2]
Martini M , Gazzaniga V , Behzadifar M ,et al. The history of tuberculosis: the social role of sanatoria for the treatment of tuberculosis in Italy between the end of the 19(th) century and the middle of the 20(th)[J]. J Prev Med Hyg, 2018,59(4):E323-E327. DOI:
10.15167/2421-4248/jpmh2018.59.4.1103
.
[3]
全国科学技术名词审定委员会. 结核病学名词[M]. 北京:科学出版社, 2019,71.
[4]
[5]
雷建平. 重新审视结核病免疫治疗研究[J]. 结核病健康教育, 2009, (2):36-45.
[6]
包晶晶,高飞. 肺结核免疫治疗的研究现状[J]. 世界最新医学信息文摘, 2020,20(10):44-45. DOI:
10.19613/j.cnki.1671-3141.2020.10.019
.
[7]
Stephanie F , Saragih M , Tambunan USF . Recent progress and challenges for drug-resistant tuberculosis treatment[J]. Pharmaceutics, 2021,13(5):592. DOI:
10.3390/pharmaceutics13050592
.
[8]
Estrada García I , Hernández Pando R , Ivanyi J . Editorial: advances in immunotherapeutic approaches to tuberculosis[J]. Front Immunol, 2021,12:684200. DOI:
10.3389/fimmu.2021.684200
.
[9]
吴雪琼,吴长有. 结核病免疫学[M]. 北京:人民卫生出版社, 2016.
[10]
Prabowo SA , Painter H , Zelmer A ,et al. RUTI vaccination enhances inhibition of mycobacterial growth ex vivo and induces a shift of monocyte phenotype in mice[J]. Front Immunol, 2019,10:894. DOI:
10.3389/fimmu.2019.00894
.
[11]
Bourinbaiar AS , Batbold U , Efremenko Y ,et al. Phase Ⅲ, placebo-controlled, randomized, double-blind trial of tableted, therapeutic TB vaccine (V7) containing heat-killed M. vaccae administered daily for one month[J]. J Clin Tuberc Other Mycobact Dis, 2020,18:100141. DOI:
10.1016/j.jctube.2019.100141
.
[12]
Van Deun A , Maug AK , Salim MA ,et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis[J]. Am J Respir Crit Care Med, 2010,182(5):684-692. DOI:
10.1164/rccm.201001-0077OC
.
[13]
Butov DA , Pashkov YN , Stepanenko AL ,et al. Phase Ⅱb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB[J]. J Immune Based Ther Vaccines, 2011,9:3. DOI:
10.1186/1476-8518-9-3
.
[14]
全国微卡菌苗临床研究协作组. 母牛分支杆菌菌苗在初治肺结核治疗中的作用[J]. 中华结核和呼吸杂志, 2001,24(1):43-47. DOI:
10.3760/j:issn:1001-0939.2001.01.017
.
[15]
唐神结,高文. 临床结核病学[M]. 2版. 北京:人民卫生出版社, 2019.
[16]
林慰慈,魏雪涛,薛彬,等译. 免疫学[M]. 2版. 北京:科学出版社. 2020.
[17]
Justiz Vaillant AA , Grella MJ . Vaccine (Vaccination)[M]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. PMID: 30422490.
[18]
Mascola JR , Fauci AS . Novel vaccine technologies for the 21st century[J]. Nat Rev Immunol, 2020,20(2):87-88. DOI:
10.1038/s41577-019-0243-3
.
[19]
Tait DR , Hatherill M , Van Der Meeren O ,et al. Final analysis of a trial of M72/AS01(E) vaccine to prevent tuberculosis[J]. N Engl J Med, 2019,381(25):2429-2439. DOI:
10.1056/NEJMoa1909953
.
[20]
[21]
刘其会,孙峰,张文宏. 结核病的辅助免疫治疗研究进展[J]. 中华实验和临床感染病杂志:电子版, 2015, (3):305-308. DOI:
10.3877/cma.j.issn.1674-1358.2015.03.002
.
[22]
Mi J , Liang Y , Liang J ,et al. The research progress in immunotherapy of tuberculosis[J]. Front Cell Infect Microbiol, 2021,11:763591. DOI:
10.3389/fcimb.2021.763591
.
[23]
Kamboj D , Gupta P ,Basil,et al. Improved Mycobacterium tuberculosis clearance after the restoration of IFN-gamma (+) TNF-alpha (+) CD4(+) T cells: Impact of PD-1 inhibition in active tuberculosis patients[J]. Eur J Immunol, 2020,50(5):736-747. DOI:
10.1002/eji.201948283
.
[24]
Leukes V , Walzl G , du Plessis N . Myeloid-derived suppressor cells as target of phosphodiesterase-5 inhibitors in host-directed therapeutics for tuberculosis[J]. Front Immunol, 2020,11:451. DOI:
10.3389/fimmu.2020.00451
.
[25]
Krug S , Parveen S , Bishai WR . Host-directed therapies: modulating inflammation to treat tuberculosis[J]. Front Immunol, 2021,12:660916. DOI:
10.3389/fimmu.2021.660916
.
[26]
Kilinç G , Saris A , Ottenhoff T ,et al. Host-directed therapy to combat mycobacterial infections[J]. Immunol Rev, 2021,301(1):62-83. DOI:
10.1111/imr.12951
.
[27]
Behr MA , Waters WR . Is tuberculosis a lymphatic disease with a pulmonary portal?[J]. Lancet Infect Dis, 2014,14(3):250-255. DOI:
10.1016/S1473-3099(13)70253-6
.
[28]
Dheda K , Schwander SK , Zhu B ,et al. The immunology of tuberculosis: from bench to bedside[J]. Respirology, 2010,15(3):433-450. DOI:
10.1111/j.1440-1843.2010.01739.x
.
[29]
Fox W , Ellard GA , Mitchison DA . Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications[J]. Int J Tuberc Lung Dis, 1999,3(10Suppl 2):S231-279.
[30]
Park J , Kim H , Kwon KW ,et al. Toll-like receptor 4 signaling-mediated responses are critically engaged in optimal host protection against highly virulent Mycobacterium tuberculosis K infection[J]. Virulence, 2020,11(1):430-445. DOI:
10.1080/21505594.2020.1766401
.
[31]
喻容,周添荣,石国民,等. 耐多药结核病患者细胞免疫功能的初步研究[J]. 实用预防医学, 2016,23(10):1199-1202. DOI:
10.3969/j.issn.1006-3110.2016.10.015
.
[32]
Téllez-Navarrete NA , Ramon-Luing LA , Muñoz-Torrico M ,et al. Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and-resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time[J]. Mol Med, 2021,27(1):76. DOI:
10.1186/s10020-021-00320-4
.
[33]
朱春玲,侯远沛,尤莲,等. 肺结核患者外周血免疫细胞水平与临床意义分析[J]. 中国人兽共患病学报, 2018,34(7):648-652. DOI:
10.3969/j.issn.1002-2694.2018.00.106
.
[34]
Bai XJ , Li HM , Yang YR ,et al. Cytokine and soluble adhesion molecule profiles and biomarkers for treatment monitoring in Re-treated smear-positive patients with pulmonary tuberculosis[J]. Cytokine, 2018,108:9-16. DOI:
10.1016/j.cyto.2018.03.009
.
[35]
Adankwah E , Harelimana JD , Minadzi D ,et al. Lower IL-7 receptor expression of monocytes impairs antimycobacterial effector functions in patients with tuberculosis[J]. J Immunol, 2021,206(10):2430-2440. DOI:
10.4049/jimmunol.2001256
.
[36]
Lee C , Bhakta S . The prospect of repurposing immunomodulatory drugs for adjunctive chemotherapy against tuberculosis: a critical review[J]. Antibiotics (Basel), 2021,10(1):91. DOI:
10.3390/antibiotics10010091
.
[37]
Stanford JL , Stanford CA . Immunotherapy of tuberculosis with Mycobacterium vaccae NCTC11659[J]. Immunobiology, 1994,191(4-5):555-563. DOI:
10.1016/S0171-2985(11)80462-6
.
[38]
Guo S , Zhao J . Immunotherapy for tuberculosis: what′s the better choice?[J]. Front Biosci (Landmark Ed), 2012,17(7):2684-2690. DOI:
10.2741/4079
.
[39]
宋敏娟,王冠莲,马秀丽,等. 卡介菌多糖核酸注射液在复治菌阳肺结核治疗中的疗效观察[J]. 临床肺科杂志, 2008,13(4):442-443. DOI:
10.3969/j.issn.1009-6663.2008.04.021
.
[40]
Uhlin M , Andersson J , Zumla A ,et al. Adjunct immunotherapies for tuberculosis[J]. J Infect Dis, 2012,205Suppl 2:S325-334. DOI:
10.1093/infdis/jis197
.
[41]
雷建平,熊国亮,胡群芳,等. 化疗加用卡介苗免疫治疗预防耐多药结核病的研究[J]. 中华预防医学杂志, 2008,42(2):86-89. DOI:
10.3321/j.issn:0253-9624.2008.02.004
.
[42]
Vekemans J , Brennan MJ , Hatherill M ,et al. Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organization consultations[J]. Vaccine, 2020,38(2):135-142. DOI:
10.1016/j.vaccine.2019.10.072
.
[43]
丁卫民. 卡介菌多糖核酸对耐多药肺结核患者临床疗效及T淋巴细胞亚群的影响[J]. 中国药物与临床, 2005,5(5):383-384. DOI:
10.3969/j.issn.1671-2560.2005.05.023
.
[44]
雷建平,王继香,傅颖媛,等. 卡介苗免疫治疗对结核病人临床疗效和T淋巴细胞亚群的影响[J]. 实用临床医学, 2002,3(1):1-5. DOI:
10.3969/j.issn.1009-8194.2002.01.001
.
[45]
Alene KA , Wangdi K , Colquhoun S ,et al. Tuberculosis related disability: a systematic review and meta-analysis[J]. BMC Med, 2021,19(1):203. DOI:
10.1186/s12916-021-02063-9
.
[46]
李红,唐神结. 微卡联合化学药物治疗初治肺结核的临床观察[J]. 中国防痨杂志, 2006,28(4):241-243. DOI:
10.3969/j.issn.1000-6621.2006.04.014
.
[47]
周志红,申红连. 母牛分枝杆菌菌苗辅助治疗复治菌阳肺结核的临床分析[J]. 中国热带医学, 2005,5(5):1009-1010, 1015. DOI:
10.3969/j.issn.1009-9727.2005.05.034
.
[48]
李生荣. 微卡配合抗结核药物治疗复治难治菌阳肺结核43例临床观察[J]. 宁夏医学杂志, 2019,41(11):1010-1012. DOI:
10.13621/j.1001-5949.2019.11.1010
.
[49]
王巍,金关甫,叶一秀. 母牛分支杆菌菌苗治疗肺结核的临床研究[J]. 中华结核和呼吸杂志, 1999,22(2):108-110. DOI:
10.3760/j:issn:1001-0939.1999.02.014
.
[50]
罗永艾,卢水华,郭述良. 母牛分支杆菌菌苗在难治性肺结核治疗中的作用[J]. 中华结核和呼吸杂志, 2000,23(2):85-88. DOI:
10.3760/j:issn:1001-0939.2000.02.008
.
[51]
丁卫民,杨俊行,王光辉. 冻干治疗用母牛分支杆菌菌苗对耐多药肺结核患者临床疗效及细胞免疫功能的影响[J]. 中国临床药理学与治疗学, 2005,10(5):559-561. DOI:
10.3969/j.issn.1009-2501.2005.05.018
.
[52]
[53]
刘晓东. 微卡免疫治疗耐多药肺结核病32例临床疗效观察[J]. 赣南医学院学报, 2010,30(3):412,414. DOI:
10.3969/j.issn.1001-5779.2010.03.036
.
[54]
李忠,张瑛. 微卡菌苗治疗老年性肺结核的疗效分析[J]. 齐齐哈尔医学院学报, 2005,26(7):740-741. DOI:
10.3969/j.issn.1002-1256.2005.07.002
.
[55]
陈珣珣,周琳,陈志宇,等. 母牛分枝杆菌菌苗应用于涂阴肺结核超短程治疗方案的临床观察[J]. 广东医科大学学报, 2019,37(3):261-264. DOI:
10.3969/j.issn.1005-4057.2019.03.007
.
[56]
王莲芝,张晶,纪滨英. 母牛分枝杆菌菌苗免疫治疗结核性渗出性胸膜炎的临床观察[J]. 临床肺科杂志, 2009,14(2):163,166. DOI:
10.3969/j.issn.1009-6663.2009.02.011
.
[57]
Sleiti AK . Dataset for measured viscosity of Polyalpha-Olefin-boron nitride nanofluids[J]. Data Brief, 2021,35:106881. DOI:
10.1016/j.dib.2021.106881
.
[58]
胡杰贵,胡先纬. 抗结核药联用乌体林斯治疗肺结核疗效观察[J]. 疾病控制杂志, 2003,7(1):37-39. DOI:
10.3969/j.issn.1674-3679.2003.01.012
.
[59]
[60]
陈建强. 乌体林斯对结核性渗出性胸膜炎的辅助治疗意义[J]. 江苏大学学报(医学版), 2003,13(2):148-149. DOI:
10.3969/j.issn.1671-7783.2003.02.031
.
[61]
Shen H , Min R , Tan Q ,et al. The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis[J]. Arch Med Sci, 2015,11(3):584-590. DOI:
10.5114/aoms.2015.52362
.
[62]
Johnson BJ , Ress SR , Willcox P ,et al. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy[J]. Cytokines Mol Ther, 1995,1(3):185-196.
[63]
Johnson BJ , Bekker LG , Rickman R ,et al. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo[J]. Tuber Lung Dis, 1997,78(3-4):195-203. DOI:
10.1016/s0962-8479(97)90026-5
.
[64]
Zhang R , Xi X , Wang C ,et al. Therapeutic effects of recombinant human interleukin 2 as adjunctive immunotherapy against tuberculosis: A systematic review and meta-analysis[J]. PLoS One, 2018,13(7):e0201025. DOI:
10.1371/journal.pone.0201025
.
[65]
Nie W , Wang J , Zeng J ,et al. Adjunctive interleukin-2 for the treatment of drug-susceptible tuberculosis: a randomized control trial in China[J]. Infection, 2022,50(2):413-421. DOI:
10.1007/s15010-021-01698-3
.
[66]
Condos R , Rom WN , Schluger NW . Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol[J]. Lancet, 1997,349(9064):1513-1515. DOI:
10.1016/S0140-6736(96)12273-X
.
[67]
Suárez-Méndez R , García-García I , Fernández-Olivera N ,et al. Adjuvant interferon gamma in patients with drug-resistant pulmonary tuberculosis: a pilot study[J]. BMC Infect Dis, 2004,4:44. DOI:
10.1186/1471-2334-4-44
.
[68]
Dawson R , Condos R , Tse D ,et al. Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis[J]. PLoS One, 2009,4(9):e6984. DOI:
10.1371/journal.pone.0006984
.
[69]
岳玉瑛,齐秀兰,范美琴,等. 胸腺肽α1联合化疗治疗肺结核疗效观察[J]. 临床医药实践, 2010,19(6):424-425. DOI:
10.3969/j.issn.1671-8631.2010.06.010
.
[70]
迟旭,陈娟,蔡华锋,等. 胸腺法新在初治涂阳肺结核患者治疗中的疗效观察[J]. 陕西医学杂志, 2017,46(8):1115-1116. DOI:
10.3969/j.issn.1000-7377.2017.08.063
.
[71]
尤辉. 抗结核药联合胸腺法新治疗初治涂阳肺结核48例的临床效果[J]. 临床医学研究与实践, 2018,3(24):1-3. DOI:
10.19347/j.cnki.2096-1413.201824001
.
[72]
童卫华. 胸腺法新对初治涂阳肺结核患者临床疗效及痰菌阴转情况的影响[J]. 中国医学创新, 2021,18(12):155-158. DOI:
10.3969/j.issn.1674-4985.2021.12.037
.
[73]
吴波,贺丹,张益,等. 胸腺法新对矽肺合并肺结核患者T淋巴细胞亚群的影响及临床意义[J]. 中国当代医药, 2020,27(30):31-33. DOI:
10.3969/j.issn.1674-4721.2020.30.009
.
[74]
Wang Y , Ke XY , Khara JS ,et al. Synthetic modifications of the immunomodulating peptide thymopentin to confer anti-mycobacterial activity[J]. Biomaterials, 2014,35(9):3102-3109. DOI:
10.1016/j.biomaterials.2013.12.049
.
[75]
刘玉松,刘月红. 支气管镜局部注射联合免疫治疗对耐药肺结核的临床疗效及机体免疫改善作用[J]. 湖南师范大学学报(医学版), 2017,14(4):151-154.
[76]
杨景峰,李玉玲,杨尚陇. 抗结核联合免疫治疗艾滋病合并肺结核的效果分析[J]. 医药前沿, 2020,10(14):68-69.
[77]
He Y , Zheng W . Evaluation of the treatment efficacy of systemic care combined with thymopentin and 2HRZE/4HR for primary tuberculosis[J]. Am J Transl Res, 2021,13(4):2891-2898.
[78]
Panda PK , Panda P , Dawman L ,et al. Efficacy and safety of thalidomide in patients with complicated central nervous system tuberculosis: a systematic review and meta-analysis[J]. Am J Trop Med Hyg, 2021,105(4):1024-1030. DOI:
10.4269/ajtmh.21-0108
.
[79]
Arshad A , Dayal S , Gadhe R ,et al. Analysis of tuberculosis meningitis pathogenesis, diagnosis, and treatment[J]. J Clin Med, 2020,9(9):2962. DOI:
10.3390/jcm9092962
.
[80]
Kim EJ , Kim JY , Choi HY ,et al. Systemic immunomodulatory effectsof combinatorial treatmentof thalidomideand dexamethasone on T cells and other immune cells[J]. Yonsei Med J, 2021,62(2):137-148. DOI:
10.3349/ymj.2021.62.2.137
.
[81]
van Toorn R , Solomons RS , Seddon JA ,et al. Thalidomide use for complicated central nervous system tuberculosis in children: insights from an observational cohort[J]. Clin Infect Dis, 2021,72(5):e136-e145. DOI:
10.1093/cid/ciaa1826
.
[82]
Schoeman JF , Springer P , van Rensburg AJ ,et al. Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study[J]. J Child Neurol, 2004,19(4):250-257. DOI:
10.1177/088307380401900402
.
[83]
Liu P , Pei N , Liu X ,et al. Thalidomide in the treatment of human immunodeficiency virus-negative tuberculous meningitis: A case report[J]. Medicine (Baltimore), 2020,99(40):e22639. DOI:
10.1097/MD.0000000000022639
.
[84]
Singhal A , Jie L , Kumar P ,et al. Metformin as adjunct antituberculosis therapy[J]. Sci Transl Med, 2014,6(263):263ra159. DOI:
10.1126/scitranslmed.3009885
.
[85]
Lachmandas E , Eckold C , Böhme J ,et al. Metformin alters human host responses to Mycobacterium tuberculosis in healthy subjects[J]. J Infect Dis, 2019,220(1):139-150. DOI:
10.1093/infdis/jiz064
.
[86]
Böhme J , Martinez N , Li S ,et al. Metformin enhances anti-mycobacterial responses by educating CD8+T-cell immunometabolic circuits[J]. Nat Commun, 2020,11(1):5225. DOI:
10.1038/s41467-020-19095-z
.
[87]
Oglesby W , Kara AM , Granados H ,et al. Metformin in tuberculosis: beyond control of hyperglycemia[J]. Infection, 2019,47(5):697-702. DOI:
10.1007/s15010-019-01322-5
.
[88]
Bishop E , Ismailova A , Dimeloe SK ,et al. Vitamin D and immune regulation: antibacterial, antiviral, anti-inflammatory[J]. JBMR Plus, 2020,5(1):e10405. DOI:
10.1002/jbm4.10405
.
[89]
Acen EL , Biraro IA , Worodria W ,et al. Impact of vitamin D status and cathelicidin antimicrobial peptide on adults with active pulmonary TB globally: a systematic review and meta-analysis[J]. PLoS One, 2021,16(6):e0252762. DOI:
10.1371/journal.pone.0252762
.
[90]
Panda S , Tiwari A , Luthra K ,et al. Status of vitamin D and the associated host factors in pulmonary tuberculosis patients and their household contacts: A cross sectional study[J]. J Steroid Biochem Mol Biol, 2019,193:105419. DOI:
10.1016/j.jsbmb.2019.105419
.
[91]
Ashenafi S , Mazurek J , Rehn A ,et al. Vitamin D₃ status and the association with human cathelicidin expression in patients with different clinical forms of active tuberculosis[J]. Nutrients, 2018,10(6):721. DOI:
10.3390/nu10060721
.
[92]
Hong Y , Kim Y , Lee JJ ,et al. Levels of vitamin D-associated cytokines distinguish between active and latent tuberculosis following a tuberculosis outbreak[J]. BMC Infect Dis, 2019,19(1):151. DOI:
10.1186/s12879-019-3798-5
.
[93]
Wejse C , Gomes VF , Rabna P ,et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial[J]. Am J Respir Crit Care Med, 2009,179(9):843-850. DOI:
10.1164/rccm.200804-567OC
.
[94]
Salahuddin N , Ali F , Hasan Z ,et al. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis′[J]. BMC Infect Dis, 2013,13:22. DOI:
10.1186/1471-2334-13-22
.
[95]
Ganmaa D , Munkhzul B , Fawzi W ,et al. High-Dose Vitamin D(3) during Tuberculosis Treatment in Mongolia. A Randomized Controlled Trial[J]. Am J Respir Crit Care Med, 2017,196(5):628-637. DOI:
10.1164/rccm.201705-0936OC
.
[96]
Jolliffe DA , Ganmaa D , Wejse C ,et al. Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data[J]. Eur Respir J, 2019,53(3):1802003. DOI:
10.1183/13993003.02003-2018
.
[97]
Zhang J , Chen C , Yang J . Effectiveness of vitamin D supplementation on the outcome of pulmonary tuberculosis treatment in adults: a meta-analysis of randomized controlled trials[J]. Chin Med J (Engl), 2019,132(24):2950-2959. DOI:
10.1097/CM9.0000000000000554
.
[98]
Wang J , Xiong K , Wang Q ,et al. Adjunctive vitamin A and D during pulmonary tuberculosis treatment: a randomized controlled trial with a 2 × 2 factorial design[J]. Food Funct, 2020,11(5):4672-4681. DOI:
10.1039/c9fo02751c
.
[99]
邱清连,邱四建,宋荣耀. 左旋咪唑辅助治疗重症肺结核疗效观察[J]. 中国医院药学杂志, 2002,22(4):231-232. DOI:
10.3321/j.issn:1001-5213.2002.04.021
.
[100]
Shamkuwar CA , Meshram SH , Mahakalkar SM . Levamisole as an adjuvant to short-course therapy in newly diagnosed pulmonary tuberculosis patients[J]. Adv Biomed Res, 2017,6:37. DOI:
10.4103/2277-9175.203162
.
[101]
Controlled clinical trial of levamisole in short-course chemotherapy for pulmonary tuberculosis. A Kenyan/Zambian/British Medical Research Council Collaborative Study[J]. Am Rev Respir Dis, 1989,140(4):990-995. DOI:
10.1164/ajrccm/140.4.990
.
[102]
Whitworth LJ , Troll R , Pagán AJ ,et al. Elevated cerebrospinal fluid cytokine levels in tuberculous meningitis predict survival in response to dexamethasone[J]. Proc Natl Acad Sci U S A, 2021,118(10):e2024852118. DOI:
10.1073/pnas.2024852118
.
[103]
中华医学会结核病学分会结核性脑膜炎专业委员会. 2019中国中枢神经系统结核病诊疗指南[J]. 中华传染病杂志, 2020,38(7):400-408. DOI:
10.3760/cma.j.cn311365-20200606-00645
.
[104]
Murthy J . Tuberculous meningitis-adjunctive therapy: corticosteroids, aspirin, or both[J]. Neurol India, 2019,67(4):1003-1005. DOI:
10.4103/0028-3886.266280
.
[105]
Suárez I , Gruell H , Heyckendorf J ,et al. Intensified adjunctive corticosteroid therapy for CNS tuberculomas[J]. Infection, 2020,48(2):289-293. DOI:
10.1007/s15010-019-01378-3
.
[106]
Yadav R . Role of aspirin as an adjuvant therapy in tuberculous meningitis in adults: The time has come for a phase Ⅲ randomized controlled trial[J]. Neurol India, 2018,66(6):1678-1679. DOI:
10.4103/0028-3886.246225
.
[107]
Whitworth L , Coxon J , van Laarhoven A ,et al. A Bayesian analysis of the association between Leukotriene A4 Hydrolase genotype and survival in tuberculous meningitis[J]. Elife, 2021,10:e61722. DOI:
10.7554/eLife.61722
.
[108]
Tobin DM , Roca FJ , Oh SF ,et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections[J]. Cell, 2012,148(3):434-446. DOI:
10.1016/j.cell.2011.12.023
.
[109]
Isiguzo G , Du Bruyn E , Howlett P ,et al. Diagnosis and management of tuberculous pericarditis: what is new?[J]. Curr Cardiol Rep, 2020,22(1):2. DOI:
10.1007/s11886-020-1254-1
.
[110]
Strang JI , Nunn AJ , Johnson DA ,et al. Management of tuberculous constrictive pericarditis and tuberculous pericardial effusion in Transkei: results at 10 years follow-up[J]. QJM, 2004,97(8):525-535. DOI:
10.1093/qjmed/hch086
.
[111]
Jurado LF , Pinzón B , De La Rosa ZR ,et al. Tuberculous pericarditis[J]. Biomedica, 2020,40(Supl. 1):23-25. DOI:
10.7705/biomedica.4911
.
[112]
Kim MS , Chang SA , Kim EK ,et al. The clinical course of tuberculous pericarditis in immunocompetent hosts based on serial echocardiography[J]. Korean Circ J, 2020,50(7):599-609. DOI:
10.4070/kcj.2019.0317
.
[113]
Wiysonge CS , Ntsekhe M , Thabane L ,et al. Interventions for treating tuberculous pericarditis[J]. Cochrane Database Syst Rev, 2017,9(9):CD000526. DOI:
10.1002/14651858.CD000526.pub2
.
[114]
Mishra NR , Panigrahi MK , Bhatt GC ,et al. Corticosteroid as an adjunct in the treatment of endobronchial tuberculosis: asystematic review & meta-analysis[J]. CurrPediatr Rev, 2020,16(1):53-60. DOI:
10.2174/1573396315666191016100615
.
[115]
丁卫民,唐神结,傅瑜. 重视气管支气管结核的综合规范治疗[J]. 中华结核和呼吸杂志, 2021,44(4):288-291. DOI:
10.3760/cma.j.cn112147-20210113-00041
.
[116]
杨伏萍,雷坤,杨松. 糖皮质激素在治疗气管支气管结核中的应用进展[J]. 结核病与肺部健康杂志, 2019,8(4):299-302. DOI:
10.3969/j.issn.2095-3755.2019.04.013
.
[117]
Fatima S , Bhaskar A , Dwivedi VP . Repurposing immunomodulatory drugs to combat tuberculosis[J]. Front Immunol, 2021,12:645485. DOI:
10.3389/fimmu.2021.645485
.
[118]
Misra UK , Kalita J , Nair PP . Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial[J]. J NeurolSci, 2010,293(1-2):12-7. DOI:
10.1016/j.jns.2010.03.025
.
[119]
Mai NT , Dobbs N , Phu NH ,et al. A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults[J]. Elife, 2018,7:e33478. DOI:
10.7554/eLife.33478
.
[120]
Misra UK , Kalita J , Sagar B ,et al. Does adjunctive corticosteroid and aspirin therapy improve the outcome of tuberculous meningitis?[J]. Neurol India, 2018,66(6):1672-1677. DOI:
10.4103/0028-3886.246278
.
[121]
Rizvi I , Garg RK , Malhotra HS ,et al. Role of aspirin in tuberculous meningitis: a systematic review and meta-analysis[J]. Neurol India, 2019,67(4):993-1002. DOI:
10.4103/0028-3886.266232
.
[122]
[123]
Wallis RS , Ginindza S , Beattie T ,et al. Lung and blood early biomarkers for host-directed tuberculosis therapies: secondary outcome measures from a randomized controlled trial[J]. PLoS One, 2022,17(2):e0252097. DOI:
10.1371/journal.pone.0252097
.
[124]
Mehta K , Spaink HP , Ottenhoff T ,et al. Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches[J]. Trends Pharmacol Sci, 2022,43(4):293-304. DOI:
10.1016/j.tips.2021.11.016
.
[125]
[126]
Harb H , Chatila TA . Mechanisms of Dupilumab[J]. Clin Exp Allergy, 2020,50(1):5-14. DOI:
10.1111/cea.13491
.
[127]
Mata-Espinosa DA , Francisco-Cruz A , Marquina-Castillo B ,et al. Immunotherapeutic effects of recombinant adenovirus encoding interleukin 12 in experimental pulmonary tuberculosis[J]. Scand J Immunol, 2019,89(3):e12743. DOI:
10.1111/sji.12743
.
[128]
Venkatasubramanian S , Cheekatla S , Paidipally P ,et al. IL-21-dependent expansion of memory-like NK cells enhances protective immune responses against Mycobacterium tuberculosis[J]. Mucosal Immunol, 2017,10(4):1031-1042. DOI:
10.1038/mi.2016.105
.
[129]
Zhao S , Song X , Zhao Y ,et al. Protective and therapeutic effects of the resuscitation-promoting factor domain and its mutants against Mycobacterium tuberculosis in mice[J]. Pathog Dis, 2015,73(3):ftu025. DOI:
10.1093/femspd/ftu025
.
[130]
D′Souza S , Souza S , Du Plessis SM ,et al. Physicochemical and biological evaluation of curdlan-poly(lactic-co-glycolic acid) nanoparticles as a host-directed therapy against Mycobacterium tuberculosis[J]. J Pharm Sci, 2022,111(2):469-478. DOI:
10.1016/j.xphs.2021.09.012
.
[131]
Sheikh JA , Khuller GK , Verma I . Immunotherapeutic role of Ag85B as an adjunct to antituberculous chemotherapy[J]. J Immune Based Ther Vaccines, 2011,9:4. DOI:
10.1186/1476-8518-9-4
.
[132]
Bai X , Oberley-Deegan RE , Bai A ,et al. Curcumin enhances human macrophage control of Mycobacterium tuberculosis infection[J]. Respirology, 2016,21(5):951-957. DOI:
10.1111/resp.12762
.
[133]
米洁,薛勇,白雪娟,等. 淋巴细胞亚群检测在结核病诊疗中的应用进展[J]. 中国防痨杂志, 2021,43(2):178-185. DOI:
10.3969/j.issn.1000-6621.2021.02.014
.
[134]
Wallis RS , Ginindza S , Beattie T ,et al. Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial[J]. Lancet Respir Med, 2021,9(8):897-908. DOI:
10.1016/S2213-2600(20)30448-3
.
[135]
Rao Muvva J , Ahmed S , Rekha RS ,et al. Immunomodulatory agents combat multidrug-resistant tuberculosis by improving antimicrobial immunity[J]. J Infect Dis, 2021,224(2):332-344. DOI:
10.1093/infdis/jiab100
.
[136]
Wang J , Wu QS , Jiang MB ,et al. Two cases of disseminated BCG disease following vaccination in the same family: case reports and review of the literature in China[J]. Hum Vaccin Immunother, 2021,17(5):1382-1386. DOI:
10.1080/21645515.2020.1819102
.
[137]
Ogishi M , Yang R , Aytekin C ,et al. Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child[J]. Nat Med, 2021,27(9):1646-1654. DOI:
10.1038/s41591-021-01388-5
.
[138]
Viatgé T , Mazières J , Zahi S ,et al. Anti-PD1 immunotherapy followed by tuberculosis infection or reactivation[J]. Rev Mal Respir, 2020,37(7):595-601. DOI:
10.1016/j.rmr.2020.06.003
.
备注信息
A
杨松，重庆市公共卫生医疗救治中心，重庆 400036，Email：
mocdef.nabuyila5gnosgnay
B
唐神结，首都医科大学附属北京胸科医院北京市结核病胸部肿瘤研究所，北京 101149，Email：
mocdef.aabnis.piv6011jsgnat
C
中华医学会结核病学分会. 结核病免疫治疗专家共识（2022年版）[J]. 中华结核和呼吸杂志, 2022, 45(7): 651-666. DOI: 10.3760/cma.j.cn112147-20220215-00120.
D
所有作者声明无利益冲突
E
北京市临床重点专科项目 (20201214)
重庆市科卫联合医学科研项目 (2019ZDXM035)
评论 （0条）
注册 登录
时间排序
- 时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
泊马度胺临床用药中国专家共识（2022年版）
中国临床肿瘤学会（CSCO）白血病专家委员会 等 白血病·淋巴瘤 2022,31(06)
成人血液病患者接种新型冠状病毒疫苗中国专家共识（2022年版）
中国康复医学会血液病康复专业委员会 等 中华血液学杂志 2022,43(05)
中国自身免疫性脑炎诊治专家共识（2022年版）
中华医学会神经病学分会神经感染性疾病与脑脊液细胞学学组 中华神经科杂志 2022,55(09)
利奈唑胺抗结核治疗专家共识（2022年版）
中华医学会结核病学分会 中华结核和呼吸杂志 2022,45(10)
分享
详细信息
表
访问与引文
阅读权限
参考文献
访问与引用
访问数据
0
0
全部时间 最近30天 最近6个月 最近12个月
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照
文献快照
N/A
N/A
AI总结中
N/A
N/A
快照内容由人工智能生成，供您参考。
你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。
0/50
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
0/2000
信息反馈
中文(简体)
英文
翻译
机器翻译功能由科大讯飞提供技术支持
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
你好！ 今天我能为您提供什么帮助？
0/30
of
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
扩写 缩写 改写 翻译
0/2000
信息反馈
历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大
翻译
润色
扩写
缩写
复制
引用
